Company Profile

Genomica Corporation
Profile last edited on: 9/25/15      CAGE:       UEI:

Business Identifier: Bioinformatics -- life sciences software.
Year Founded
1996
First Award
1999
Latest Award
1999
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1745 38th Street
Boulder, CO 80301
   (720) 565-4500
   N/A
   N/A
Location: Single
Congr. District: 02
County: Boulder

Public Profile

In January 2002, Genomica was acquired by Exelixis, Inc. For reasons not quite clear, while retaining a full license for theirown use, Exelixis sold on Genomica only three months later at a major loss to Vizualize. A pharmacogenomics software company, Genomica was founded to commercialize bioinformatics tools developed by Dr. Thomas G. Marr and his team at Cold Spring Harbor Laboratory in New York, Genomica's tools combine clinical, epidemiology, genetic, molecular biology, and biochemistry applications into a single software environment that enables scientists to accelerate genetic discoveries and pharmacogenomics. Genomica's software is used in the gene discovery process to develop custom drug applications and accelerate time to market for new drugs. The software supports a range of research activities and provides data that can be accessed and used by pharmaceutical and biotechnology companies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : GNOM
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1999 1 NIH $100,000
Project Title: Flexible; Robust; & Automated Microarray Analysis
1999 1 NIH $99,809
Project Title: Analyzing Gene Expression For Cancer Gene Discovery
1999 1 NIH $193,433
Project Title: Flexible, Robust, & Automated Microarray Analysis

Key People / Management

  Teresa W Ayers -- CEO

  Thomas Marr -- President & CSO

  Daniel C Weaver

Company News

There are no news available.